Loading…
Each decision rolls up every audited claim behind one longevity question — what each creator said, how it stacks up against the literature, and the verdict.
Watch — for healthy adults without diabetes, the n=1 data is interesting but not yet linked to better outcomes.
For most adults with elevated ApoB and any additional risk factor: yes. The risk-benefit case is well-studied.
For aggressive primary prevention: defensible. The exact threshold is opinion-driven and not in any guideline yet.
Yes. One-time test, genetically determined, changes cardiovascular risk-stratification meaningfully.
For intermediate-risk patients: clarifying. With family history at low baseline: arguably the most cost-effective screen.